Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee Osteoarthritis
A legfontosabb adatok
- Ki végzi
- RegenLab France SAS
- Hol
- Franciaország13 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 280 fő, tervezett
- Kezdés
- 2023. aug. 21.
- Befejezés
- 2026. aug. 30.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Regen Matrix-PRP-XLHA
- Hylan G-F 20
- Placebo
- A regiszteradat frissítve
- 2026. február 10.
Ki vehet részt
- Életkor
- 40 év – 90 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 31 feltétel megnézéseKevesebb
Ki vehet részt
- Tibiofemoral knee osteoarthrosis according to ACR criteria
- Tibiofemoral knee osteoarthrosis grade 3-4 according to the Kellgren \& Lawrence grading scale, as defined on knee radiographs (less than 3 months old: face view, schuss view, profile and patellar axial view at 30°)
- Symptomatic knee osteoarthrosis as evidenced by pain on walking (WOMAC A1 assessed in the last 24 hours on a scale of 0 to 100 mm: 50 ≤ DM 90 or reduced joint function (WOMAC C total score assessed or within the previous 24 hours based on a scale of 0-100-mm: 50 ≤ WOMAC C ≤ 90)
- Patient able to understand the requirements of the trial and who has signed a free and informed consent prior to study entry
- Patient able to read and understand the written instructions
- Patient able to complete the self-assessment questionnaires
Ki nem vehet részt
- Knee surgery planned in the next 6 months
- Last PRP or PRP/HA injection received in the last year
- Last viscosupplementation received in the past 6 months
- Last corticosteroid injection received in the past 3 months
- Use of gluco-corticosteroids (except inhaled) and level III analgesics in the last 3 months and non-steroidal anti-inflammatory drug in the last 2 weeks
- Treatment with AAAL initiated within the last 6 months
- Patient affected by autoimmune disease (rheumatoid arthritis, lupus, Hashimoto's disease and Bechterew's syndrome)
- Patient affected by a knee infection in the past 6 months
- History of allergy to hyaluronic acid
- Hematologic or clotting disorders (thrombocytopenia) or blood coagulation (deficit-blood dyscrasia)
- Malignant diseases (especially bone or haematological)
- Patients with serious, no-stabilized pathologies (cardiovascular disease, active peptic ulcer, digestive hemorrhage)
- Acute infection
- Patients with cancer or with an immuno-deprassant treatment ongoing
- Anemia (HGB<10 g/dl)
- Tibiofemoral knee osteoarthrosis grade I or II according to the Kellgren and Lawrence grading scale
- Chronic inflammatory rheumatism other than arthritis (polyarthrosis, etc.)
- Clinical signs of local knee inflammation (redness or warmth of the knee joint)
- Patients with coagulation times outside the reference values
- Venous or lymphatic stasis in the corresponding limb
- Participation in another clinical trial for osteoarthritis of the knee in the last year
- Participation in another clinical trial, ongoing or completed within the last 3 months
- Patient unable to comply with the constraints of the protocol, in particular a patient whose mental state does not allow him/her to patient's mental state does not allow him/her to understand the nature, objectives and possible consequences of the study
- Pregnant or breastfeeding women or women who expect to become pregnant during the study
- Any other reason which may interfere with the proper conduct of the study, in the investigator's opinion
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
In this clinical trial the investigator assess the safety and efficacy of a single injection of a combination of cross-linked hyaluronic acid (HA) with autologous platelet-rich plasma (PRP) obtained with the RegenMatrix medical device to improve symptoms of moderate to severe knee osteoarthitis (grade III-IV Kellgren-Lawrence).
A vizsgálat 3 csoportja
- RegenMatrix-PRP-XLHAA vizsgált kezelés
Patients randomized in this group will receive a single injection of a combination of platelet-rich plasma plus cross-linked hyaluronic acid, prepared with the medical device RegenMatrix.
Kezelés: Regen Matrix-PRP-XLHA
- Hylan G-F 20Már használt kezelés, összehasonlításként
Patients randomized in this group will receive a single injection of cross-linked hyaluronic acid Hylan G-F 20 (Synvisc-One®).
- PlaceboPlacebo, összehasonlításként
Patients randomized in this group will receive a single injection of saline solution (0.9% NaCl)
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Multicenter, Randomized Double-blind Study to Compare the Safety and Performance of a Combination of A-PRP and XLHA Prepared With the RegenMatrix Medical Device, to Hylan G-F 20 XLHA and Placebo to Treat Moderate/Severe Knee Osteoarthritis
- A regiszteradat frissítve
- 2026. február 10.